AngioDynamics, Inc. (ANGO) EPS Estimated At $0.21

June 20, 2018 - By Tina Thibodeau

AngioDynamics, Inc. (NASDAQ:ANGO) LogoInvestors sentiment increased to 1.46 in 2018 Q1. Its up 0.20, from 1.26 in 2017Q4. It improved, as 17 investors sold AngioDynamics, Inc. shares while 40 reduced holdings. 25 funds opened positions while 58 raised stakes. 34.89 million shares or 2.93% more from 33.90 million shares in 2017Q4 were reported.
Pub Employees Retirement Association Of Colorado, Colorado-based fund reported 16,356 shares. Moreover, Pinebridge Lp has 0.04% invested in AngioDynamics, Inc. (NASDAQ:ANGO) for 89,798 shares. Cornercap Counsel owns 0.12% invested in AngioDynamics, Inc. (NASDAQ:ANGO) for 47,125 shares. 12,571 are owned by Element Limited Liability. Wellington Management Grp Limited Liability Partnership has invested 0% in AngioDynamics, Inc. (NASDAQ:ANGO). Principal invested in 0% or 298,168 shares. Loomis Sayles & Lp accumulated 0% or 575 shares. Fisher Asset Management Ltd Liability Corporation invested in 12,477 shares. Glenmede Tru Na reported 0% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO). 51,066 were accumulated by Teton Advisors Incorporated. Foundry Ptnrs Ltd Company reported 388,070 shares stake. Ny State Common Retirement Fund holds 78,947 shares or 0% of its portfolio. 79,965 are held by Acadian Asset Mngmt Ltd Llc. Moreover, Gamco Invsts Inc Et Al has 0.01% invested in AngioDynamics, Inc. (NASDAQ:ANGO) for 50,000 shares. Ls Invest Limited Com stated it has 1,331 shares or 0% of all its holdings.

Analysts expect AngioDynamics, Inc. (NASDAQ:ANGO) to report $0.21 EPS on July, 17.They anticipate $0.02 EPS change or 10.53 % from last quarter’s $0.19 EPS. ANGO’s profit would be $7.73 million giving it 26.71 P/E if the $0.21 EPS is correct. After having $0.25 EPS previously, AngioDynamics, Inc.’s analysts see -16.00 % EPS growth. The stock increased 1.58% or $0.35 during the last trading session, reaching $22.44. About 150,906 shares traded. AngioDynamics, Inc. (NASDAQ:ANGO) has risen 30.75% since June 20, 2017 and is uptrending. It has outperformed by 18.18% the S&P500.

AngioDynamics, Inc. (NASDAQ:ANGO) Ratings Coverage

Among 3 analysts covering Angiodynamics (NASDAQ:ANGO), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Angiodynamics had 5 analyst reports since January 5, 2018 according to SRatingsIntel. Canaccord Genuity maintained AngioDynamics, Inc. (NASDAQ:ANGO) on Monday, April 2 with “Hold” rating. Craig Hallum downgraded the shares of ANGO in report on Friday, January 5 to “Hold” rating. As per Thursday, January 4, the company rating was maintained by Canaccord Genuity. Canaccord Genuity maintained the stock with “Hold” rating in Thursday, March 29 report. The firm has “Outperform” rating given on Tuesday, April 3 by Raymond James.

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company has market cap of $825.89 million. The firm provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities. It has a 623.33 P/E ratio. It also offers AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

More important recent AngioDynamics, Inc. (NASDAQ:ANGO) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: Clinical Hold For Crispr, Gilead Study Meets Endpoint, Akers Gets Grace Time” on June 01, 2018, also Nasdaq.com published article titled: “Research Report Identifies AngioDynamics, Kaiser Aluminum, Mammoth Energy Services, Meridian Bioscience …”, Benzinga.com published: “Benzinga’s Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid …” on June 15, 2018. More interesting news about AngioDynamics, Inc. (NASDAQ:ANGO) was released by: Benzinga.com and their article: “Benzinga’s Daily Biotech Pulse: Sarepta’s DMD Gene Therapy, Anika’s Flunked Trial, Eidos To Commence Trading” with publication date: June 20, 2018.

AngioDynamics, Inc. (NASDAQ:ANGO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: